Search results
AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker
Zacks via Yahoo Finance· 8 months agoAbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD),...
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoAbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and...
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Zacks via Yahoo Finance· 2 years agoAbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for...
AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine
Zacks via Yahoo Finance· 2 years agoAbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to...
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
Zacks via Yahoo Finance· 2 years agoAbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's...
AbbVie Q3 Preview: Can Shares Continue Their Run?
Zacks via Yahoo Finance· 2 years agoThe Zacks Medical sector has performed slightly better than the S&P 500 YTD, down 18.7% vs. the general market’s roughly 20% decline. A titan in the...
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Zacks via Yahoo Finance· 6 months agoAbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel...
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
Zacks via Yahoo Finance· 1 year agoAbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two...
AbbVie (NYSE:ABBV) shareholders have earned a 14% CAGR over the last five years
Simply Wall St. via Yahoo Finance· 11 months agoAbbVie Inc. (NYSE:ABBV) shareholders might be concerned after seeing the share price drop 16% in the...
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
Zacks via Yahoo Finance· 10 months agoAbbVie Inc. ABBV reported adjusted earnings of $2.91 per share for second-quarter 2023, beating the...